In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Neuronetics Brightens Outlook For Neuro Devices

Executive Summary

Neuronetics Inc. forged a new specialty of sorts, the interventional psychiatrist. Unlike other interventional approaches, the externally applied NeuroStar delivers transcranial magnetic stimulation to the precise area of the brain responsible for intractable depression. The device is changing the lives of psychiatrists who launched “TMS” clinics, hoping to capture the early success, and potentially creating opportunities for medical devices designed to treat other brain-related disorders.

You may also be interested in...

Research Briefs: Study Updates From Neuronetics, Edwards

Neuronetics starts study enrollment for its NeuroStar transcranial magnetic stimulation to treat postpartum depression. Edwards delays enrollment for Sapien XT Cohort A of the PARTNER II trial. More research news.

Device Start-Ups Inch Closer To Elusive Epilepsy Treatment

Despite the availability of more than 20 anti-epilepsy drugs, surgery, and a neurostimulation therapy that’s been available for 15 years, a large proportion of the three million patients in the US with epilepsy continue to have seizures. Emerging device companies aim to provide a solution for them.

Brainsway Closes Gap Between Devices And Drugs With Noninvasive Deep Brain Stimulation

Following a series of private investments and strategic acquisitions, Brainsway Ltd. announced it had received CE mark approval for a new therapy for chronic neuropathic pain, bringing another potential neurostimulation treatment to market in Europe. Meanwhile, the company reported positive interim results on its clinical trial of a treatment for obsessive compulsive disorder, adding to positive results from a pivotal multicenter trial studying its therapy for major depression. These trials validate a new device treatment for conditions that neurologists and psychiatrists typically treat with drugs.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts